<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="glofit-tisli-rrdlbcl-zhou">
    <meta name="study:title" content="PB3225 - Efficacy and safety of Glofitamab combined with Tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: A pilot study in China">
    <meta name="study:fileName" content="Abstracts/GLOFIT-TISLI-RRDLBCL-ZHOU-PB3225.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Glofitamab,Bispecific antibodies,Tislelizumab,PD-1 inhibitor,Obinutuzumab,Monoclonal Antibody">

    <title>PB3225: Glofitamab + Tislelizumab in R/R DLBCL (Zhou) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> <style>
        /* Lightbox styles */
        .lightbox {
            display: none;
            position: fixed;
            z-index: 999;
            padding-top: 50px;
            left: 0;
            top: 0;
            width: 100%;
            height: 100%;
            overflow: auto;
            background-color: rgba(0,0,0,0.9);
        }
        .lightbox-content {
            margin: auto;
            display: block;
            width: 90%; /* Adjusted for potentially wider/taller images */
            max-width: 1200px; /* Increased max-width */
            max-height: 90vh; /* Increased max-height */
        }
        .lightbox-caption {
            margin: auto;
            display: block;
            width: 80%;
            max-width: 700px;
            text-align: center;
            color: #ccc;
            padding: 10px 0;
            height: 50px;
        }
        .lightbox-close {
            position: absolute;
            top: 15px;
            right: 35px;
            color: #f1f1f1;
            font-size: 40px;
            font-weight: bold;
            transition: 0.3s;
        }
        .lightbox-close:hover,
        .lightbox-close:focus {
            color: #bbb;
            text-decoration: none;
            cursor: pointer;
        }
        .figure-image-thumbnail { /* Renamed for clarity */
            cursor: zoom-in;
            transition: 0.3s;
            max-width: 100%;
            height: auto;
            border: 1px solid var(--sobi-light-gray); /* Optional: adds a light border */
            border-radius: 4px; /* Optional: rounds corners */
        }
        .figure-image-thumbnail:hover {opacity: 0.7;}
    </style>
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3225 - Glofitamab + Tislelizumab in R/R DLBCL (Pilot Study)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=10)</h4>
                    <p>R/R DLBCL Pts (≥18y, ≥2 prior LOT). Aim: Evaluate efficacy & safety of Glofitamab + Tislelizumab.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Pilot Study)</h4>
                    <p>C1: Obi D1, Glofit D8(2.5mg)/D15(10mg). C2+: Glofit 30mg D1, Tislelizumab 200mg D8. Up to 12 cycles.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=9 evaluable, mF/U 6.3mo)</h4>
                    <p>ORR: <span class="highlight-value">66.7%</span> (6/9). CR: <span class="highlight-value">55.6%</span> (5/9). OS & PFS rates at data cutoff: 50%.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Favorable safety. CRS: G1 50%, G2 10%. No G3/4 CRS/ICANS. G3/4 hematol. AEs 50%. Encouraging outcomes.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3225 - Efficacy and safety of Glofitamab combined with Tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: A pilot study in China</h1>
            <p class="abstract-sub-header">De Zhou, Wenjuan Yu, Ehsan Ghoushi, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3225 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Prognosis for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor.</li>
                        <li>Glofitamab (CD20×CD3 bispecific antibody) monotherapy showed a 39% CR rate in a Phase 2 study.</li>
                        <li>Efficacy may be limited by T-cell numbers/function; Immune Checkpoint Inhibitors (ICIs) like Tislelizumab (anti-PD-1) may restore T-cell activity.</li>
                        <li>ICIs combined with CAR T-cell therapy have shown prolonged DOR.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the efficacy and safety of glofitamab combined with tislelizumab in patients with R/R DLBCL in a pilot study.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Pilot study (China). Registered Phase 2: ChiCTR2400091464.</li>
                        <li>Patient Population: DLBCL pts (≥18 years), R/R after ≥2 prior lines of therapy.</li>
                        <li>Treatment Regimen (21-day cycles):
                            <ul class="list-circle list-inside ml-4">
                                <li>Cycle 1: Obinutuzumab 1000mg D1, Glofitamab 2.5mg D8, Glofitamab 10mg D15.</li>
                                <li>Subsequent Cycles (if no G≥2 CRS in C1): Glofitamab 30mg D1, Tislelizumab 200mg D8.</li>
                            </ul>
                        </li>
                        <li>Treatment Duration: Pts with SD/PR continued up to 12 cycles. Pts with CR after 6 cycles entered follow-up.</li>
                        <li>Primary Endpoint: Safety.</li>
                        <li>Secondary Endpoints: CR rate, ORR, DOR, PFS, OS.</li>
                        <li>Response Assessment: 2014 Lugano criteria. AE/CRS Grading: CTCAE v5.0 / ASTCT criteria.</li>
                        <li>Enrollment Period: Feb 20, 2024 - June 11, 2024.</li>
                    </ul>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=10)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median Age: 68.5 years (range, 25-80).</li>
                        <li>Gender: 6 Female, 4 Male.</li>
                        <li>Median Prior Lines of Therapy: 3.5.</li>
                        <li>All patients refractory to last line of therapy.</li>
                        <li>Median Follow-up: 6.3 months (range, 2.4-11.5). No patients lost to follow-up.</li>
                    </ul>
                </div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy & Safety Results</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Safety (N=10):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CRS: 1 patient Grade 2, 5 patients Grade 1.</li>
                        <li>No Grade 3-4 CRS or ICANS observed.</li>
                        <li>Grade 3-4 Hematological AEs: 5 patients.</li>
                        <li>One death due to COVID-19 during Cycle 2.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Efficacy (N=9 evaluable):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Overall Response Rate (ORR): 66.7% (6/9).</li>
                        <li>Complete Response (CR): 55.6% (5/9).</li>
                        <li>Progressive Disease (PD): 33.3% (3/9).</li>
                        <li>Disease Recurrence among responders: 1/6 patients.</li>
                        <li>OS and PFS rates at data cutoff (Jan 31, 2025): Both 50%.</li>
                    </ul>
                     <div class="chart-container my-4">
                        <svg id="glofitTisliResponseChart" width="350" height="280"></svg>
                        <div id="glofitTisliResponseLegend" class="legend"></div>
                    </div>

                    <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure 1: Study Design and Swimmer Plots</h3>
                        <img id="zhouFigure1Thumbnail" src="Assets/ZhouFigure1.jpg" alt="Figure 1: Study design and swimmer plots for participants" class="figure-image-thumbnail mx-auto rounded-lg shadow-md" onerror="this.onerror=null;this.src='https://placehold.co/600x400/EBF4FA/1E3A8A?text=Figure+1+Not+Available';">
                        <p class="text-xs text-center mt-2 italic">Figure 1: Study design (A) and swimmer plots for participants (B). Click image to enlarge.</p>
                    </div>

                    <div id="zhouFigure1Lightbox" class="lightbox">
                        <span class="lightbox-close" id="closeZhouFigure1Lightbox">&times;</span>
                        <img class="lightbox-content" id="zhouFigure1LightboxImage">
                        <div class="lightbox-caption" id="zhouFigure1LightboxCaption"></div>
                    </div>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>The combination of glofitamab and tislelizumab demonstrated a favorable safety profile in this pilot study of 10 R/R DLBCL patients.</li>
                <li>Encouraging clinical outcomes were observed, with an ORR of 66.7% and a CR rate of 55.6% in the 9 efficacy-evaluable patients.</li>
                <li>A Phase 2, single-arm, prospective study (ChiCTR2400091464) has been registered to further evaluate the efficacy and safety of this combination.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ASTCT, American Society for Transplantation and Cellular Therapy; CAR T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; ChiCTR, Chinese Clinical Trial Registry; CR, Complete Remission; CRR, Complete Response Rate; CRS, Cytokine Release Syndrome; CT, Computed Tomography; CTCAE, Common Terminology Criteria for Adverse Events; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; DOR, Duration of Remission; G, Grade; Glofit, Glofitamab; ICI, Immune Checkpoint Inhibitor; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; IV, Intravenous; LOT, Lines of Therapy; mg, Milligram; mF/U, Median Follow-up; Obi, Obinutuzumab; ORR, Overall Response Rate; OS, Overall Survival; PD, Progressive Disease; PD-1, Programmed Death-1; PET, Positron Emission Tomography; PFS, Progression-Free Survival; PR, Partial Remission; Pts, Patients; R/R, Relapsed or Refractory; SD, Stable Disease; Tx, Treatment; y, Years.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Zhou D, Yu W, Ghoushi E, et al. Efficacy and safety of Glofitamab combined with Tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: A pilot study in China. Abstract #PB3225 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3225 | Abstract Release: 05/14/25 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
        // Lightbox JavaScript for Figure 1
        document.addEventListener('DOMContentLoaded', function() {
            const lightbox = document.getElementById('zhouFigure1Lightbox');
            const lightboxImg = document.getElementById('zhouFigure1LightboxImage');
            const lightboxCaption = document.getElementById('zhouFigure1LightboxCaption');
            const thumbnail = document.getElementById('zhouFigure1Thumbnail');
            const closeBtn = document.getElementById('closeZhouFigure1Lightbox');

            if (thumbnail) {
                thumbnail.onclick = function(){
                    lightbox.style.display = "block";
                    lightboxImg.src = this.src; // Use thumbnail src for lightbox
                    lightboxCaption.innerHTML = this.alt;
                }
            }

            if (closeBtn) {
                closeBtn.onclick = function() {
                    lightbox.style.display = "none";
                }
            }
             if (lightbox) {
                lightbox.onclick = function(event) {
                    if (event.target === lightbox) { 
                        lightbox.style.display = "none";
                    }
                }
            }
        });

        function drawGlofitTisliResponseChart(containerId, legendContainerId) {
            const chartTitle = "Response to Glofitamab + Tislelizumab (N=9)";
            // ORR 66.7% (6/9), CR 55.6% (5/9). PR = ORR - CR = 66.7 - 55.6 = 11.1%
            // PD 33.3% (3/9)
            const chartData = [
                { response: "CR", rate: 55.6, color: "var(--sobi-teal)" },
                { response: "PR", rate: 11.1, color: "var(--sobi-light-teal-bg)" },
                { response: "PD", rate: 33.3, color: "var(--sobi-red-light)" }
            ];
            const orrRate = chartData.find(d => d.response === "CR").rate + chartData.find(d => d.response === "PR").rate;

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);
            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 280);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");
            const margin = { top: 60, right: 20, bottom: 50, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

            const xScale = d3.scaleBand()
                .domain(chartData.map(d => d.response))
                .range([0, chartWidth])
                .padding(0.3);

            const yScale = d3.scaleLinear().domain([0, 100]).range([chartHeight, 0]);

            g.append("g").attr("transform", `translate(0,${chartHeight})`).call(d3.axisBottom(xScale))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px");

            g.append("g").call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text").attr("class", "axis-text").style("font-size", "10px");
            
            g.append("text").attr("transform", "rotate(-90)").attr("y", 0 - margin.left + 10).attr("x", 0 - (chartHeight / 2))
                .attr("dy", "1em").style("text-anchor", "middle").attr("class", "axis-label").text("Response Rate (%)");

            g.append("g").attr("class", "grid")
                .call(d3.axisLeft(yScale).ticks(5).tickSize(-chartWidth).tickFormat(""))
                .selectAll("line").style("stroke", "var(--sobi-light-gray)").style("stroke-opacity", "0.7");

            g.selectAll(".bar").data(chartData).enter().append("rect")
                .attr("class", "bar").attr("x", d => xScale(d.response)).attr("y", d => yScale(d.rate))
                .attr("width", xScale.bandwidth()).attr("height", d => chartHeight - yScale(d.rate))
                .attr("fill", d => d.color).attr("rx", 3).attr("ry", 3);

            g.selectAll(".bar-label").data(chartData).enter().append("text")
                .attr("class", "chart-label").attr("x", d => xScale(d.response) + xScale.bandwidth() / 2)
                .attr("y", d => yScale(d.rate) - 5).attr("text-anchor", "middle")
                .style("font-size", "10px").style("fill", "var(--sobi-dark-text)")
                .text(d => `${d.rate.toFixed(1)}%`);
            
            svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 - 5)
                .attr("text-anchor", "middle").style("font-size", "13px").style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)").text(chartTitle);
            
            svg.append("text").attr("x", svgWidth / 2).attr("y", margin.top / 2 + 15)
                .attr("text-anchor", "middle").style("font-size", "11px").style("font-weight", "bold")
                .style("fill", "var(--sobi-teal-darker)").text(`Overall Response Rate (ORR): ${orrRate.toFixed(1)}%`);

            const legendItems = legendContainer.selectAll(".legend-item").data(chartData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.response);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => { clearTimeout(timeout); func(...args); };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawGlofitTisliChart = debounce(() => drawGlofitTisliResponseChart("#glofitTisliResponseChart", "#glofitTisliResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawGlofitTisliChart);
        document.addEventListener('DOMContentLoaded', debouncedDrawGlofitTisliChart);
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawGlofitTisliChart, 0); 
        }
    </script>
</body>
</html>
